TFDP2

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, TFDP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TFDP2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TFDP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TFDP2 expression acts as an unfavorable survival marker.

LUSC, COAD, and HNSC are the cancer types where TFDP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
LUSCOSMedianII,III,IV0.1470.743.00224view →
COADOSMedianAll0.1680.806.00215view →
HNSCOSMedianAll0.1670.751.0099view →
UCECOSMedianIV0.2310.592.0366view →
LUADOSMedianII,III,IV0.5400.709.0264view →
Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TFDP2–LUSC (OS)

Kaplan–Meier survival curve for TFDP2 mutant vs wild-type samples in LUSC.

Open the LUSC breakdown →

Exploration